Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China

被引:4
|
作者
Sun, Shan [1 ]
Chen, Kai [2 ]
Kong, Xuehua [2 ]
Tian, Wenjun [3 ]
Niu, Siqiang [1 ]
机构
[1] Chongqing Med Univ, Dept Lab Med, Affiliated Hosp 1, Chongqing, Peoples R China
[2] Chongqing Med Univ, Coll Lab Med, Chongqing, Peoples R China
[3] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Clin Lab Med, Jinan, Shandong, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
carbapenem-resistant Enterobacterales; carbapenemase genes; aztreonam/avibactam; ceftazidime/avibactam; KLEBSIELLA-PNEUMONIAE; MOLECULAR EPIDEMIOLOGY; ANTIBIOTIC-RESISTANCE; AZTREONAM-AVIBACTAM; INFECTION; STRAINS; CRE;
D O I
10.2147/IDR.S357396
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: This study aimed to understand the distribution characteristics of carbapenemase genes and assess the antimicrobial activities of aztreonam/avibactam (ATM/AVI) and ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Enterobacterales (CRE) isolates in Chongqing, Southwest China. Methods: CRE isolates and their clinical information were collected from 22 hospitals covering all the five regions across Chongqing between January 1, 2016 and December 31, 2017. PCR was used to screen for common carbapenemase genes. And minimum inhibitory concentrations (MICs) were determined by broth microdilution method. Results: A total of 312 unduplicated CRE isolates (eg, 206 Klebsiella pneumoniae, 43 Escherichia coli, and 42 Enterobacter cloacae) were collected during the two-year study period. Among these CRE isolates, 92.3% carried carbapenemase genes, with a majority of isolates carrying single bla(KPC-2) (47.1%) or single bla(NDM/IPM) (36.2%) and 8.9% of isolates carrying two or three carbapenemase genes. Notably, 95.6% (197/206) K. pneumoniae, 86.0% (37/43) E. coli and 88.1% (37/42) E. cloacae harbored carbapenemase genes. In addition, bla(KPC-2) was prevalent in K. pneumoniae (70.4%), while bla(NDM) was predominant in E. coli (83.7%) and E. cloacae (78.6%). Besides, only metallo-beta-lactamase (MBL) genes were detected in the CRE isolates from children. Overall, 0.0%, 48.1%, 59.0%, 61.5% and 63.1% of the CRE isolates were resistant to ATM/AVI, CAZ/AVI, nitrofurantoin, amikacin and trimethoprim/sulfamethoxazole, respectively. 99.7% of the total 312 isolates could be killed by ATM/AVI with the MIC 1 mu g/mL, whereas CAZ/AVI showed good antibacterial activity (98.0% susceptible) against the bla(KPC-2)-carriers with the MIC50/90 values of 1/4 mu g/mL. Conclusion: The distribution features of carbapenemase genes in Chongqing were comprehensively illustrated in terms of species and sources of CRE for the first time in this multi-center study that covered all the geographical locations across Chongqing. ATM/AVI showed superior activity against all CRE isolates regardless of their genotype, whereas CAZ/AVI was active against almost all KPC-producers.
引用
收藏
页码:2243 / 2251
页数:9
相关论文
共 50 条
  • [21] Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China
    Zhang, P.
    Shi, Q.
    Hu, H.
    Hong, B.
    Wu, X.
    Du, X.
    Akova, M.
    Yu, Y.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (01) : 124.e1 - 124.e4
  • [22] In-vitro Susceptibility Testing Methods for Ceftazidime-avibactam against Carbapenem-resistant Enterobacterales: Comparison with Reference Broth Microdilution Method
    Sharma, Bhawna
    Sreenivasan, Priya
    Angrup, Archana
    Kaur, Satinder
    Rana, Sudesh
    Kundu, Jyoti
    Biswal, Manisha
    Ray, Pallab
    CURRENT DRUG SAFETY, 2023, 18 (04) : 563 - 570
  • [23] Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study
    Almangour, Thamer A.
    Ghonem, Leen
    Aljabri, Ahmad
    Alruwaili, Alya
    Al Musawa, Mohammed
    Damfu, Nader
    Almalki, Mesfer S.
    Alattas, Majda
    Abed, Hossam
    Naeem, Doaa
    Almalki, Nawaf
    Alhifany, Abdullah A.
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 211 - 221
  • [24] Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance
    Shields, Ryan K.
    Nguyen, M. Hong
    Hao, Binghua
    Kline, Ellen G.
    Clancy, Cornelius J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (08)
  • [25] In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM
    Kuai, Junyang
    Zhang, Yawei
    Lu, Binghuai
    Chen, Hongbin
    Zhang, Yulin
    Li, Henan
    Wang, Yuanyuan
    Wang, Qi
    Wang, Hui
    Wang, Xiaojuan
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 3171 - 3182
  • [26] Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals
    Castanheira, Mariana
    Doyle, Timothy B.
    Deshpande, Lalitagauri M.
    Mendes, Rodrigo E.
    Sader, Helio S.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 58 (05)
  • [27] Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae Ceftazidime-avibactam against CR- KP infections
    Gu, Jie
    Xu, Jie
    Zuo, Ting-ting
    Chen, Yan-bin
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 26 : 20 - 25
  • [28] In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany
    Kresken, Michael
    Korte-Berwanger, Miriam
    Pfennigwerth, Niels
    Gatermann, Soren G.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 25 : 337 - 338
  • [29] Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021)
    Sader, Helio S.
    Mendes, Rodrigo E.
    Carvalhaes, Cecilia G.
    Kimbrough, John H.
    Castanheira, Mariana
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (02):
  • [30] Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope (vol 22, 21, 2023)
    Taha, Rawan
    Kader, Ola
    Shawky, Sherine
    Rezk, Shahinda
    ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2023, 22 (01)